EFSD and Amylin Pharmaceuticals Paul Langerhans Grant

Named for the scientist who first described the islet cells of the pancreas, Paul Langerhans grants of up to Euro 100,000 for basic science and Euro 300,000 for clinical research are available from a partnership between the European Foundation for the Study of Diabetes and Amylin Pharmaceuticals.

The focus of the grant is to improve the management of diabetes through research into the roles of the gastrointestinal tract in the pathogenesis of the disease, and to improve treatment of diabetes in the obese through advances in bariatric surgery.

The deadline for applications is 20 April 2010. To find out more and download an application form, please follow the link below.

EFSD/Amylin Pharma. Paul Langerhans Grant